Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4829-4838

  Bek, Emily Jane ^a   Hussain, Khairunnisa Mohamed ^a   Phuektes, Patchara ^a   Kok, Chee Choy ^a   Gao, Qiang ^b   Cai, Fang ^b   Gao, Zhenglun ^b   McMinn, Peter Charles ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Sinovac Biotech Co Ltd   (China)

Author keywords

Cross protection; Human enterovirus 71; Inactivated vaccine

Indexed keywords

FORMALDEHYDE; INACTIVATED VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE; CONTROLLED STUDY; CROSS PROTECTION; ENTEROVIRUS 71; ENTEROVIRUS 71 INFECTION; FEMALE; GENOTYPE; HUMAN ENTEROVIRUS 71 INFECTION; IMMUNIZATION; LETHALITY; MOUSE; MYOSITIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS LOAD; VIRUS STRAIN;

EID: 79960652939     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.070     Document Type: Article

References (44)

1. McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clinical Infectious Diseases 2001;32(2):236-42.
2. Huang C-C, Liu C-C, Chang Y-C, Chen C-Y, Wang S-T, Yeh T-F. Neurologic complications in children with enterovirus 71 infection. New England Journal of Medicine 1999;341(September (13)):936-42.
3. Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet 1999;354(9191):1682-6.
4. Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerging Infectious Disease 2003;9(4):461-8.
5. Zhang Y, Tan X-J, Wang H-Y, Yan D-M, Zhu S-L, Wang D-Y, et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. Journal of Clinical Virology 2009;44(4):262-7.
6. Brown BA, Oberste MS, Alexander Jr JP, Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. Journal of Virology 1999;73(12):9969-75.
7. Deshpande JM, Nadkarni SS, Francis PP. Enterovirus 71 isolated from a case of acute flaccid paralysis in India represents a new genotype. Current Science 2003;84(10):1350-3.
8. Huang S-W, Hsu Y-W, Smith DJ, Kiang D, Tsai H-P, Lin K-H, et al. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. Journal of Clinical Microbiology 2009;47(September (11)):3653-62.
9. Ooi MH, Wong SC, Podin Y, Akin W, del Sel S, Mohan A, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clinical Infectious Diseases 2007;44(5): 646-56.
10. Mao L-X, Wu B, Bao W-X, Han F-A, Xu L, Ge Q-J, et al. Epidemiology of hand, foot, and mouth disease and genotype characterization of enterovirus 71 in Jiangsu, China. Journal of Clinical Virology 2010;49(2):100-4.
11. Chen X, Zhang Q, Li J, Cao W, Zhang J -X, Zhang L, et al. Analysis of recombination and natural selection in human enterovirus 71. Virology 2010;398(2):251-61.
12. Yip C, Lau S, Zhou B, Zhang M-X, Tsoi H-W, Chan K-H, et al. Emergence of enterovirus 71 "double-recombinant" strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Archives of Virology 2010;155(9):1413-24.
13. Solomon TA, Willison HB. Infectious causes of acute flaccid paralysis. Current Opinion in Infectious Diseases 2003;16(5):375-81.
14. McMinn P, Lindsay K, Perera D, Chan HM, Chan KP, Cardosa MJ. Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. Journal of Virology 2001;75(August (16)):7732-8.
15. Xu J, Qian Y, Wang S, Serrano JMG, Li W, Huang Z, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 2010;28(20): 3516-21.
16. Lee BY, Wateska AR, Bailey RR, Tai JHY, Bacon KM, Smith KJ. Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine 2010;28(29):7731-6.
17. Chung Y-C, Ho M-S, Wu J-C, Chen W-J, Huang J-H, Chou S-T, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008;26(15):1855-62.
18. Chung C-Y, Chen C-Y, Lin S-Y, Chung Y-C, Chiu H-Y, Chi W-K, et al. Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield. Vaccine 2010;28(43):6951-7.
19. Chen H-F, Chang M-H, Chiang B-L, Jeng S-T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 2006;24(15):2944-51.
20. Wu C-N, Lin Y-C, Fann C, Liao N-S, Shih S-R, Ho M-S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001;20(5-6):895-904.
21. Miao LY, Pierce C, Gray-Johnson J, DeLotell J, Shaw C, Chapman N, et al. Monoclonal antibodies to VP1 recognize a broad range of enteroviruses. Journal of Clinical Microbiology 2009;47(October (10)):3108-13.
22. Li X, Mao C, Ma S, Wang X, Sun Z, Yi Y, et al. Generation of neutralizing monoclonal antibodies against enterovirus 71 using synthetic peptides. Biochemical and Biophysical Research Communications 2009;390(4):1126-8.
23. Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF, Xu W-B, Qin C, Zhang LF. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010;28(46):7444-51.
24. Tung W, Bakar S, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genetic Vaccines and Therapy 2007;5(6).
25. Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. Journal of Virology 2010;84(January (1)):661-5.
26. Sinovac developing vaccine for hand, foot and mouth disease. Worldwide Biotech; 2008.
27. Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC. The molecular basis of mouse adaptation by human enterovirus 71. Journal of General Virology 2008;89(July (7)):1622-32.
28. Reed LJ, Muench H. A simple method of estimating fifty percent endpoint. American Journal of Hygiene 1938;27:493-7.
29. Iiai T, Watanabe H, Seki S, Sugiura K, Hirokawa K, Utsuyama M, et al. Ontogeny and development of extrathymic T cells in mouse liver. Immunology 1992;77:556-63.
30. Paoletti LC, Pinel J, Kennedy RC, Kasper DL. Maternal antibody transfer in baboons and mice vaccinated with a Group B streptococcal polysaccharide conjugate. Journal of Infectious Diseases 2000;181(February (2)):653-8.
31. Chen C-S, Yao Y-C, Lin S-C, Lee Y-P, Wang Y-F, Wang J-R, et al. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. Journal of Virology 2007;81(September (17)):8996-9003.
32. Jia C, Liu J, Li W, Ma C, Lin S, Hao Y, et al. The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virology Journal 2010;7(47).
33. Wang S-M, Liu C-C, Tseng H-W, Wang J-R, Huang C-C, Chen Y-J, et al. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clinical Infectious Diseases 1999;29(1):184-90.
34. Wong KT, Chua KB, Lam SK. Immunohistochemical detection of infected neurons as a rapid diagnosis of enterovirus 71 encephalomyelitis [2]. Annals of Neurology 1999;45(2):271-2.
35. Ng DKK, Law AKW, Cherk SWW, Mak KL. First fatal case of enterovirus 71 infection in Hong Kong. Hong Kong Medical Journal 2001;7(2):193-6.
36. Foo DGW, Alonso S, Chow VTK, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes and Infection 2007;9(11):1299-306.
37. Wang J-R, Tuan Y-C, Tsai H-P, Yan J-J, Liu C-C, Su I-J. Change of major genotype of enterovirus 71 in outbreaks of hand-foot-and-mouth disease in Taiwan between 1998 and 2000. Journal of Clinical Microbiology 2002;40(January (1)):10-5.
38. Bek EJ, McMinn PC. Recent advances in research on human enterovirus 71. Future Virology 2010;5(4):453-68.
39. Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, et al. An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. Journal of Virology 2007;81(September (17)):9386-95.
40. Tee KK, Lam TT-Y, Chan YF, Bible JM, Kamarulzaman A, Tong CYW, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. Journal of Virology 2010;84(April (7)):3339-50.
41. Lin T-Y, Twu S-J, Ho M-S, Chang L-Y, Lee C-Y. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerging Infectious Diseases 2003; 9(3).
42. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996;14(8):735-46.
43. Davis JA. The Triple A Approach to Ensuring Animal Welfare. Animal Welfare Information Center Bulletin 1999/2000;10(3-4).
44. Foltz CJ, Ullman-Cullere M. Guidelines for Assessing the Health and Condition of Mice. Lab Animal 1999;28(4):28-31.